Shopping Cart 0
Cart Subtotal
USD 0

Hemorrhage-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 6000

Details

Hemorrhage-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemorrhage-Pipeline Review, H2 2017, provides an overview of the Hemorrhage (Hematological Disorders) pipeline landscape.

Hemorrhage is a disease which results in excessive bleeding. Causes of hemorrhage include liver disease, bleeding disorder, high blood pressure, injury and aneurysm. Symptoms include nausea or vomiting, difficulty swallowing, loss of coordination, loss of consciousness, severe headache and tingling or numbness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemorrhage-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hemorrhage (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemorrhage (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II and Phase 0 stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Hemorrhage (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hemorrhage (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Hemorrhage (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hemorrhage (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hemorrhage (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hemorrhage (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hemorrhage (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hemorrhage (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hemorrhage-Overview

Hemorrhage-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemorrhage-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemorrhage-Companies Involved in Therapeutics Development

Cellphire Inc

Grifols SA

Haemostatix Ltd

Hemorrhage-Drug Profiles

(fibrinogen (human) + thrombin (human))-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethinylestradiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PeproStat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Postpartum Hemorrhage-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombosomes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemorrhage-Dormant Projects

Hemorrhage-Product Development Milestones

Featured News & Press Releases

Mar 20, 2017: Ergomed Initiates Phase II study of topical PeproStat in Intraoperative surgical haemostatis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Hemorrhage, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Hemorrhage, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Hemorrhage-Pipeline by Cellphire Inc, H2 2017

Hemorrhage-Pipeline by Grifols SA, H2 2017

Hemorrhage-Pipeline by Haemostatix Ltd, H2 2017

Hemorrhage-Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Cellphire Inc

Grifols SA

Haemostatix Ltd

Company Profile

Company Profile Title

Hemorrhage-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemorrhage-Pipeline Review, H2 2017, provides an overview of the Hemorrhage (Hematological Disorders) pipeline landscape.

Hemorrhage is a disease which results in excessive bleeding. Causes of hemorrhage include liver disease, bleeding disorder, high blood pressure, injury and aneurysm. Symptoms include nausea or vomiting, difficulty swallowing, loss of coordination, loss of consciousness, severe headache and tingling or numbness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemorrhage-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hemorrhage (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemorrhage (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II and Phase 0 stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Hemorrhage (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hemorrhage (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Hemorrhage (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hemorrhage (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hemorrhage (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hemorrhage (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hemorrhage (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hemorrhage (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hemorrhage-Overview

Hemorrhage-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemorrhage-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemorrhage-Companies Involved in Therapeutics Development

Cellphire Inc

Grifols SA

Haemostatix Ltd

Hemorrhage-Drug Profiles

(fibrinogen (human) + thrombin (human))-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethinylestradiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PeproStat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Postpartum Hemorrhage-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombosomes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemorrhage-Dormant Projects

Hemorrhage-Product Development Milestones

Featured News & Press Releases

Mar 20, 2017: Ergomed Initiates Phase II study of topical PeproStat in Intraoperative surgical haemostatis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Hemorrhage, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Hemorrhage, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Hemorrhage-Pipeline by Cellphire Inc, H2 2017

Hemorrhage-Pipeline by Grifols SA, H2 2017

Hemorrhage-Pipeline by Haemostatix Ltd, H2 2017

Hemorrhage-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Cellphire Inc

Grifols SA

Haemostatix Ltd